Wir würden uns freuen, wenn du Teil unserer Community wirst. Tritt unserem Discord bei um dich mit uns und anderen Mitgliedern zu vernetzen!

Ticker
LYSX.F

Price
61.53
Stock movement up
+0.29 (0.47%)
Company name
Multi Units France - Lyxor Euro Stoxx 50 (DR) UCITS ETF
Exchange
(F
,
Currency
EUR
)
Marktkapitalisierung
-
Ent-Wert
-
Preis/Umsatz
-
Preis/Buch
-
Div-Ertrag
-
Div Wachstum
-
Wachstumsjahre
-
FCF-Ausschüttung
-
Nachlaufendes KGV
-
Forward P/E
-
PEG
-
EPS-Wachstum
-
1 Jahr Rückkehr
19.24%
3-Jahres-Rendite
-
5-Jahres-Rendite
-
10-Jahres-Rendite
-
Zuletzt aktualisiert: 2025-11-24

DIVIDENDS

LYSX.F keine Dividenden ausschüttet

BEWERTUNG

Bewertungskennzahlen

Loading...
Daten zu den Bewertungsverhältnissen
Nachlaufendes KGV-
Preis zu OCF-
Preis zu FCF-
Preis zu EBITDA-
EV zu EBITDA-

Bewertung (Umsatz/Buchwert)

Loading...
Bewertungsdaten (Umsatz/Buchwert)
Preis zu Umsatz-
Preis zum Buchen-
EV zu Verkäufen-

FINANZEN

BESTANDSINFORMATIONEN

Aktienchart

Loading...
Daten zum Aktienkurs
Öffnen Sie61.13
Tageshöchststand61.67
Tägliches Tief61.11
Tägliches Volumen0K
Allzeithoch64.41
1-Jahres-Analystenschätzung-
Beta-
EPS (TTM)-
Dividende je Aktie0.00
Ex-Div-Datum-
Nächstes Ergebnisdatum-

Nachteiliges Potenzial

Loading...
Nachteilige potenzielle Daten
LYSX.FS&P500
Aktueller Preisrückgang vom Allzeithoch-4.47%-4.13%
Höchster Preisrückgang-15.33%-19.00%
Datum des höchsten Rückgangs8 Apr 20258 Apr 2025
Durchschnittlicher Rückgang vom Höchststand-2.42%-2.73%
Durchschnittliche Zeit bis zum neuen Höchststand9 days6 days
Maximale Zeit bis zum neuen Höchststand66 days89 days
UNTERNEHMENSDATEN
LYSX.F (Multi Units France - Lyxor Euro Stoxx 50 (DR) UCITS ETF) company logo
Marketcap
-
Kategorie Marktkapitalisierung
Beschreibung
The Lyxor EURO STOXX 50 (DR) UCITS ETF is a UCITS compliant exchange traded fund that aims to track the benchmark index EURO STOXX 50 Net Return EUR, offsetting the impact of daily variations of the index local currency vs. the USD. The USD-hedged share class offers the simplicity of a daily currency hedge mechanism that is embedded in the investment product, representing an efficient solution to manage the foreign-exchange risk.The EURO STOXX 50 Net Return EUR is Europe's leading Blue-chip index for the Eurozone providing a Blue-chip representation of supersector leaders in the Eurozone from 50 stocks and over 12 Eurozone countries. It captures approximately 60% of the free float market capitalisation of the EURO STOXX Total Market Index (TMI), which in turn covers approximately 95% of the free float market capitalisation of the represented countries. More information on www.stoxx.com.
Mitarbeiter
Website
Investor Relations
-
SEC-Anmeldungen
CEO
Land
Germany
Stadt
Art des Bestands
-
CCC-Status
-
Häufigkeit der Ausschüttung
-
VERANSTALTUNGEN UND PRÄSENTATIONEN
VeranstaltungenPräsentationen
Loading...
DAS GESCHÄFT VERSTEHEN
Loading...
UNTERNEHMENSNACHRICHTEN
Alle NachrichtenPresseveröffentlichungen
Thinking about what to do with your GL Events shares? Whether you are sizing up an entry point or reassessing your position after a strong rally, now is a great time to take stock of what is really ha...
9. September 2025
If you are weighing your next move with Banca IFIS, you are not alone. After all, the stock has served up a mix of intrigue and promise this year, catching plenty of attention across the financial lan...
9. September 2025
The cider brand has added a high-contrast NaviLens QR code to its cans.
9. September 2025
BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty
9. September 2025
Temenos also the winner for Bank Deposit Transformation with Credem and listed in the 2025 IDC FinTech Rankings Top 25GRAND-LANCY, Switzerland, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Temenos (SIX: TEMN), ...
9. September 2025
The Management Board of Artea Bankas has approved changes to the management and organizational structure. The Management Board has received a notice from board member Mindaugas Rudys regarding his res...
9. September 2025
Novartis agreed to buy Tourmaline Bio in a roughly $1.4 billion-dollar deal that boosts its cardiovascular drug pipeline with access to the targeted therapy drug pacibekitug. The Swiss pharmaceuti...
9. September 2025
Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmali...
9. September 2025